Supernus Pharmaceuticals Inc - SUPN - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 26, 2013

Supernus Pharmaceuticals Inc - SIC # 2834

Ticker	Exchange	SIC #	Website	Latest Ticker
SUPN	Nasdaq	2834	http://www.supernus.com/	6.86 +0.21
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Supernus Pharmaceuticals Inc Nasdaq stocks posting largest percentage increases - May 24th, 2013 4:04 pm SUPERNUS PHARMACEUTICALS INC Financials - May 21st, 2013 11:04 am Supernus to Present at Two Investor Conferences - May 20th, 2013 2:30 pm SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits - May 20th, 2013 8:00 am 5 Stocks Setting Up to Break Out - May 17th, 2013 11:47 am SUPERNUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report - May 15th, 2013 7:19 am 8 Stocks Under $10 Trending Sharply Higher - May 14th, 2013 9:53 pm Narrower-than-Expected Loss at Supernus - May 14th, 2013 7:40 am Supernus Pharmaceuticals Reports First Quarter 2013 Financial Results - May 13th, 2013 2:00 pm SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements - May 13th, 2013 7:47 am Q1 2013 Supernus Pharmaceuticals Earnings Release - After Market Close - May 13th, 2013 5:07 am SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fin - May 9th, 2013 8:03 am Supernus Announces First Quarter 2013 Earnings Conference Call and Webcast - May 6th, 2013 2:30 pm SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits - May 6th, 2013 8:31 am Supernus Announces Closing of $90 Million of 7.50% Convertible Senior Secured Notes Due 2019 - May 6th, 2013 6:00 am Supernus Secures Financing For CNS Pipeline Development - May 5th, 2013 5:55 am Generic Drug Pricing Pressure Remains in Western Europe, While Central and Eastern Europe, Latin America and Parts of Asia Eye Fairly Strong Growth in Generic Drugs - May 2nd, 2013 9:28 am Supernus rebounds with call buying - Apr 29th, 2013 1:14 am Supernus Prices Offering of $75 Million of 7.50% Convertible Senior Secured Notes Due 2019 - Apr 26th, 2013 8:00 am Supernus Prices Offering of $75 Million of 7.50% Convertible Senior Secured Notes Due 2019 - Apr 26th, 2013 7:00 am View All Current Headlines >>